1
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTER ENDED SEPTEMBER 30, 1998
COMMISSION FILE NUMBER 0-20165
STERIS CORPORATION
(Exact name of registrant as specified in its charter)
OHIO 34-1482024
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
5960 HEISLEY ROAD, 440-354-2600
MENTOR, OHIO 44060-1834 (Registrant's telephone number
(Address of principal executive offices) including area code)
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [ X ] No [ ].
The number of Common Shares outstanding as of September 30, 1998: 68,277,909
================================================================================
2
PART I FINANCIAL INFORMATION
STERIS CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(IN THOUSANDS) (UNAUDITED)
======================================================================================================
SEPTEMBER 30, MARCH 31,
1998 1998
-------------- ---------------
ASSETS
Current assets:
Cash and cash equivalents $ 25,077 $ 17,172
Accounts receivable 196,599 203,992
Inventories 110,619 87,405
Current portion of deferred income taxes 25,354 23,609
Prepaid expenses and other assets 15,301 12,154
-------------- ---------------
TOTAL CURRENT ASSETS 372,950 344,332
Property, plant, and equipment 322,394 289,658
Accumulated depreciation (97,613) (84,366)
-------------- ---------------
Net property, plant, and equipment 224,781 205,292
Intangibles 282,047 240,488
Accumulated amortization (69,289) (66,516)
-------------- ---------------
Net intangibles 212,758 173,972
Deferred income taxes 11,726 5,710
Other assets 2,817 3,019
-------------- ---------------
TOTAL ASSETS $ 825,032 $ 732,325
============== ===============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term indebtedness $ 2,200 $ 2,200
Accounts payable 37,514 37,213
Accrued expenses and other 136,519 130,241
-------------- ---------------
TOTAL CURRENT LIABILITIES 176,233 169,654
Long-term indebtedness 202,250 152,879
Other liabilities 51,341 50,840
-------------- ---------------
TOTAL LIABILITIES 429,824 373,373
Shareholders' equity:
Serial preferred shares, without par value, 3,000 shares authorized;
no shares outstanding
Common Shares, without par value, 300,000 shares authorized; issued
and outstanding shares of 68,278 at September 30, 1998 and 68,020 at
March 31, 1998, excluding 201 and 458 treasury shares, respectively 233,616 230,477
Retained earnings 168,125 135,009
Cumulative translation adjustment (6,533) (6,534)
-------------- ---------------
TOTAL SHAREHOLDERS' EQUITY 395,208 358,952
-------------- ---------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 825,032 $ 732,325
============== ===============
See notes to consolidated condensed financial statements.
2
3
STERIS CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED)
===============================================================================
THREE MONTHS ENDED SIX MONTHS ENDED
SEPTEMBER 30 SEPTEMBER 30
----------------------------- -----------------------------
1998 1997 1998 1997
------------ ------------ ------------- ------------
Net revenues $ 191,125 $ 173,383 $ 364,900 $ 328,517
Cost of goods and services sold 101,621 95,196 194,082 183,496
------------ ------------ ------------- ------------
Gross profit 89,504 78,187 170,818 145,021
Costs and expenses:
Selling, informational, and administrative 50,693 46,573 100,224 87,716
Research and development 6,074 5,974 12,103 11,930
------------ ------------ ------------- ------------
56,767 52,547 112,327 99,646
------------ ------------ ------------- ------------
Income from operations 32,737 25,640 58,491 45,375
Interest expense (2,325) (873) (4,719) (1,395)
Interest income and other 360 315 515 375
------------ ------------ ------------- ------------
Income before income taxes 30,772 25,082 54,287 44,355
Income tax expense 12,001 9,773 21,171 17,299
------------ ------------ ------------- ------------
Net income $ 18,771 $ 15,309 $ 33,116 $ 27,056
============ ============ ============= ============
Net income per share - basic $ 0.27 $ 0.23 $ 0.49 $ 0.40
============ ============ ============= ============
Net income per share - diluted $ 0.27 $ 0.22 $ 0.47 $ 0.39
============ ============ ============= ============
See notes to consolidated condensed financial statements.
3
4
STERIS CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(IN THOUSANDS) (UNAUDITED)
==================================================================================================================
SIX MONTHS ENDED
SEPTEMBER 30
---------------------------------
1998 1997
-------------- ---------------
OPERATING ACTIVITIES
Net income $ 33,116 $ 27,056
Adjustments to reconcile net income to
net cash provided by operating activities:
Depreciation and amortization 15,225 10,129
Deferred income taxes (7,761) 525
Other items (1,776) (2,180)
Changes in operating assets and liabilities:
Accounts receivable 12,037 (5,355)
Inventories (20,329) (7,209)
Other assets (2,135) 143
Accounts payable and accruals (1,533) (17,964)
-------------- ---------------
NET CASH PROVIDED BY OPERATING ACTIVITIES 26,844 5,145
INVESTING ACTIVITIES
Purchases of property, plant, equipment, and patents (31,458) (13,722)
Investment in businesses (39,992) (126,505)
Sale of assets 0 35,577
Proceeds from sales of marketable securities 0 2,044
-------------- ---------------
NET CASH USED IN INVESTING ACTIVITIES (71,450) (102,606)
FINANCING ACTIVITIES
Payments on long-term obligations (589) (62)
Borrowing under credit facility 50,000 110,000
Purchase of treasury shares (2,495) (2,386)
Proceeds from exercise of stock options 2,937 3,624
Tax benefits from exercise of stock options 2,657 1,008
-------------- ---------------
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 52,510 112,184
Effect of exchange rate changes on cash and cash equivalents 1 516
-------------- ---------------
INCREASE IN CASH AND CASH EQUIVALENTS 7,905 15,239
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 17,172 20,576
-------------- ---------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 25,077 $ 35,815
============== ===============
See notes to consolidated condensed financial statements.
4
5
STERIS CORPORATION
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED)
PERIODS ENDED SEPTEMBER 30, 1998 AND 1997
A. - REPORTING ENTITY
STERIS Corporation (the "Company" or "STERIS") develops, manufactures, and
markets infection prevention, contamination prevention, microbial reduction, and
surgical support systems, products, services, and technologies for healthcare,
scientific, research, food, and industrial Customers throughout the world. The
Company has over 4,500 Associates (employees) worldwide, including more than
1,700 direct sales, service, and field support personnel. Customer Support
facilities are located in major global market centers with manufacturing
operations in the United States, Canada, Germany, and Finland. STERIS operates
in a single business segment.
B. - BASIS OF PRESENTATION
The accompanying unaudited consolidated condensed financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q; they do not
include all of the information and footnotes required by generally accepted
accounting principles for complete audited financial statements. Accordingly,
the reader of these financial statements may wish to refer to the audited
consolidated financial statements of STERIS filed with the Securities and
Exchange Commission as part of STERIS's Form 10-K for the year ended March 31,
1998.
The accompanying consolidated condensed financial statements have been prepared
in accordance with STERIS's customary accounting practices and have not been
audited. Management believes that the financial information included herein
reflects all adjustments necessary for a fair presentation of interim results
and all such adjustments are of a normal and recurring nature. The interim
results reported are not necessarily indicative of the results to be expected
for the fiscal year ending March 31, 1999.
The consolidated financial statements include the accounts of the Company and
its wholly-owned subsidiaries. Intercompany accounts and transactions have been
eliminated upon consolidation. Certain reclassifications have been made to the
Company's prior year financial statements to agree with current year
classifications.
5
6
STERIS CORPORATION
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED)
C. - EARNINGS PER SHARE
Following is a summary, in thousands, of Common Shares and Common Share
equivalents outstanding used in the calculations of earnings per share:
THREE MONTHS ENDED SIX MONTHS ENDED
SEPTEMBER 30 SEPTEMBER 30
--------------------------------- -----------------------------
1998 1997 1998 1997
-------------- ------------ ------------- ------------
Weighted average Common Shares
outstanding - basic 68,326 67,980 68,222 67,925
Dilutive effect of stock options 2,429 2,290 2,496 2,166
-------------- ------------ ------------- ------------
Weighted average Common Shares
and equivalents - diluted 70,755 70,270 70,718 70,091
============== ============ ============= ============
On July 28, 1998, the Company announced a 2-for-1 stock split by means of a 100%
stock dividend on STERIS Common Shares. The stock split was effective August 24,
1998 to shareholders of record on August 10, 1998. The net income per common
share and the weighted average number of common shares outstanding as well as
number of shares issued and outstanding for all periods shown on the
Consolidated Condensed Financial Statements and footnotes have been adjusted to
reflect this stock split.
D. - COMPREHENSIVE INCOME
Comprehensive income amounted to $19,434 and $14,887, net of tax, for the
quarters ended September 30, 1998 and 1997, respectively, an increase of 30.5%.
Comprehensive income amounted to $33,117 and $27,572, net of tax, for the six
months ended September 30, 1998 and 1997, respectively, an increase of 20.1%.
The difference between net income and comprehensive income is the changes in
cumulative translation adjustment for the periods presented.
6
7
STERIS CORPORATION
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED)
E. - INVENTORIES
Inventories were as follows:
SEPTEMBER 30, MARCH 31,
1998 1998
--------------------- -------------------
Raw material $42,071 $33,007
Work in process 24,982 17,666
Finished goods 43,566 36,732
--------------------- -------------------
$110,619 $87,405
===================== ===================
The increase in inventories was due to an increase in the necessary stock levels
to support product sales and anticipated future product sales, along with the
acquisition of businesses.
F. - FINANCING
During the first fiscal quarter 1998, STERIS increased the amount available for
borrowing under its unsecured revolving Credit Facility from $125,000 to
$215,000. The amended Credit Facility expires September 30, 2001 and may be used
for general corporate purposes. Loans under the Credit Facility will bear
interest, at STERIS's option, at either KeyBank National Association's prime
rate or LIBOR rates plus 0.25 percent to 0.35 percent. The Credit Facility
contains customary covenants which include maintenance of certain financial
ratios. Outstanding borrowings under the Credit Facility were $195,000 at
September 30, 1998.
The Company has now repurchased 1.7 million Common Shares as a part of its
previously announced open market buy-back program.
G. - CONTINGENCIES
There are various pending lawsuits and claims arising out of the conduct of
STERIS's business. In the opinion of management, the ultimate outcome of these
lawsuits and claims will not have a material adverse effect on STERIS's
consolidated financial position or results of operations. STERIS presently
maintains product liability insurance coverage in amounts and with deductibles
that it believes are prudent.
The Company employs approximately 600 persons who are covered by domestic
collective bargaining agreements. Approximately 500 of these Associates are
covered by agreements that will expire before June 30, 1999. Management
considers its relationship with these Associates to be good.
7
8
STERIS CORPORATION
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED)
H. - ACQUISITIONS
In late September 1998, the Company completed the acquisition of Hausted Inc.
Hausted is a leading provider of mobile systems for surgical and diagnostic
patient positioning and transport. The acquisition has been accounted for as a
purchase transaction. Early in the third quarter fiscal 1999, the Company
acquired the assets of Royal Sterilization Systems of Arizona. The business,
located in Nogales, Arizona, currently provides contract sterilization and
microbial reduction services to producers of medical devices in the Southwestern
United States and Mexico.
8
9
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
RESULTS OF OPERATIONS
- ---------------------
Net revenue increased by 10.2% to $191.1 million in the second quarter fiscal
1999 from $173.4 million in the second quarter fiscal 1998. Net revenue
increased by 11.1% to $364.9 million in the first six months of fiscal 1999 from
$328.5 million in the same period in fiscal 1998. Revenues in North America in
the fiscal second quarter were $169.3 million, an increase of 15.9% from the
same prior year period. International revenues were $21.8 million, a decline of
$5.5 million, or 20.3%, from last year's second quarter. Revenues in North
America in the first six months of fiscal 1999 were $325.5 million, an increase
of 16.1% from the same prior year period. International revenues were $39.4
million, a decrease of $8.8 million, or 18.3%, from the same prior year period.
Revenues from consumables and services were 53.5% of sales for the quarter, up
from 50.5% last year. Revenues of the North America Healthcare Division grew by
13.7% in the fiscal second quarter, highlighted by an increase of 19.9% in
infection prevention revenues to $100.5 million. Surgical Support revenues in
the North America Healthcare Division were essentially the same as the prior
year fiscal second quarter but were 31.8% higher than this year's first quarter.
Exclusive of a discontinued, low margin, private label product line from a prior
acquisition, the Division's Surgical Support second quarter revenues increased
by $1.5 million, or 4.4%, from the second quarter last year. Revenues of the
North America Healthcare Division grew by 14.1% in the first six months of
fiscal 1999, from the same prior year period. Scientific, Management Services,
and Other revenue increased by 12.9% to $48.1 million in the second quarter
fiscal 1999 from $42.6 million in the second quarter fiscal 1998. The Scientific
Division's North America fiscal second quarter sales increased by 26.3% from the
prior year to $32.4 million. Included were a 29.2% increase in sales of
scientific systems and products and a 22.6% increase in management services.
Scientific, Management Services, and Other revenue increased by 18.9% to $91.0
million in the first six months of fiscal 1999 from $76.5 million in the same
period in fiscal 1998. The Scientific Division's North America first six months
of fiscal 1999 sales increased by 25.8% from the prior year to $62.2 million.
The costs of products and services sold increased by 6.7% to $101.6 million in
the second quarter fiscal 1999 from $95.2 million in the second quarter fiscal
1998. The costs of products and services sold increased by 5.8% to $194.1
million for the first six months of fiscal 1999 from $183.5 million for the
first six months of fiscal 1998. The cost of products and services sold as a
percentage of net revenue was 53.2% for the second quarter fiscal 1999 compared
to 54.9% for the same period in fiscal 1998. The decrease in the cost of
products and services sold as a percentage of net revenue for the second quarter
fiscal 1999 resulted principally from the increased percentage of revenues from
higher margin consumables, accessories, and services, and the product expansion
and expense reduction synergies from the effective integration of acquired
businesses.
Selling, informational, and administrative expenses increased by 8.8% to $50.7
million in the second quarter fiscal 1999 from $46.6 million in the second
quarter fiscal 1998. Selling, informational, and administrative expenses
increased by 14.3% to $100.2 million in the first six months of fiscal 1999 from
$87.7 million in the same period of fiscal 1998. The expenses as a
9
10
percentage of net revenue decreased to 26.5% in the second quarter fiscal 1999
from 26.8% in the second quarter fiscal 1998. The increase was attributable to
the continued investments in customer support systems, information technology
systems, and to support the increased level of business.
Research and development expenses increased by 1.7% to $6.1 million in the
second quarter fiscal 1999 from $6.0 million in the second quarter fiscal 1998.
Research and development expenses increased by 1.5% to $12.1 million in the
first six months of fiscal 1999 from $11.9 million in the same period fiscal
1998.
Interest expense increased by 166.3% to $2.3 million in the second quarter
fiscal 1999 from $0.9 million in the second quarter fiscal 1998. Interest
expense increased by 238.3% to $4.7 million in the first six months of fiscal
1999 from $1.4 million in the same period fiscal 1998. The increase was due to
the additional borrowing under the Credit Facility for the purchase of acquired
companies.
Net income for the second quarter of fiscal 1999 increased by 22.6% to $18.8
million ($.27 per share) from $15.3 million ($.22 per share) in the same period
fiscal 1998. Net income for the first six months of fiscal 1999 increased by
22.4% to $33.1 million ($.47 per share) from $27.1 million ($.39 per share) in
the same period fiscal 1998.
LIQUIDITY AND CAPITAL RESOURCES
- -------------------------------
The Company had $25.1 million in cash and cash equivalents as of September 30,
1998, compared to $17.2 million of the same at March 31, 1998. The increase was
primarily attributable to cash received from operations , borrowings, and the
exercise of stock options and partially offset by the cash used for acquisitions
of businesses and purchases of property, plant, and equipment.
Accounts receivable decreased by 3.6% to $196.6 million as of September 30,
1998, compared to $204.0 million at March 31, 1998. The decrease resulted from
increased collections.
Inventory increased by 26.6% to $110.6 million as of September 30, 1998,
compared to $87.4 million at March 31, 1998. The increase was due to an increase
in the necessary stock levels to support product sales and anticipated future
product sales, along with the acquisition of businesses.
Prepaid expenses and other assets increased by 25.9% to $15.3 million as of
September 30, 1998, compared to $12.2 million at March 31, 1998. The increase
was mainly due to the increase in supplies and the acquisition of Hausted.
Property, plant, and equipment increased by 11.3% to $322.4 million as of
September 30, 1998, compared to $289.7 million at March 31, 1998. The increase
was due to investments in informational technology systems, manufacturing
equipment, and distribution systems.
Intangibles increased by 17.3% to $282.0 million as of September 30, 1998,
compared to $240.5 million at March 31, 1998. The increase was primarily a
result of the acquisition of Hausted.
10
11
Noncurrent deferred income taxes increased by 105.4% to $11.7 million as of
September 30, 1998, compared to $5.7 million at March 31, 1998. The increase was
due to the acquisition of businesses and other.
Current liabilities increased by 3.9% to $176.2 as of September 30, 1998,
compared to $169.7 million at March 31, 1998. The increase was due to the
acquisition of businesses and other.
Long-term indebtedness increased by 32.3% to $202.3 million as of September 30,
1998, compared to $152.9 at March 31, 1998. The increase was due to the
borrowing to acquire businesses.
Other liabilities were $51.3 million as of September 30, 1998, compared to $50.8
million of the same at March 31, 1998. The increase was due to periodic
accruals.
During the first fiscal quarter 1998, STERIS increased the amount available for
borrowing under its unsecured revolving Credit Facility from $125 million to
$215 million. The amended Credit Facility expires September 30, 2001 and may be
used for general corporate purposes. Loans under the Credit Facility will bear
interest, at STERIS's option, at either KeyBank National Association's prime
rate or LIBOR rates plus 0.25 percent to 0.35 percent. The Credit Facility
contains customary covenants which include maintenance of certain financial
ratios. Outstanding borrowing under the Credit Facility was $195 million at
September 30, 1998.
The Company has no material commitments for capital expenditures. The Company
believes that its cash requirements will increase due to increased sales
requiring more working capital, accelerated research and development, and
potential acquisitions or investments in complementary businesses. However, the
Company believes that its available cash, cash flow from operations, and sources
of credit will be adequate to satisfy its capital needs for the foreseeable
future.
CONTINGENCIES
- -------------
For a discussion of contingencies, see Note G to the consolidated condensed
financial statements.
SEASONALITY
- -----------
Historical data indicates that financial results of acquired businesses were
subject to recurring seasonal fluctuations. A number of factors have contributed
to the seasonal patterns, including sales promotion and compensation programs,
customer buying patterns of capital equipment, and international business
practices. Sales and profitability of certain of the acquired and consolidated
product lines have historically been disproportionately weighted toward the
latter part of each quarter and each fiscal year. Various changes in business
practices resulting from the integration of acquired businesses into STERIS,
including the change to a March ending fiscal year, may alter the historical
patterns of the previously independent businesses.
11
12
YEAR 2000 DATE CONVERSION
- -------------------------
An issue affecting STERIS and most other companies is how computer systems and
applications recognize and process date-sensitive information. Some older
computer programs were written using two digits rather than four to define the
applicable year. As a result, those computer programs have time-sensitive
software that recognize a date using "00" as the year 1900 rather than the year
2000. Without corrective actions, this could cause a system failure or
miscalculations causing disruptions of operations, including, among other
things, a temporary inability to process transactions, send invoices, or engage
in similar normal business activities.
The Company has investigated the impact of the year 2000 issue on its products
and does not anticipate any effect on the performance of its products. The
Company is in the process of assessing and implementing necessary changes for
all areas of the Company's business which could be impacted; these include such
areas as business computer systems, technical infrastructure, plant floor
equipment, building infrastructure, end-user computing, and suppliers. The
Company has initiated a project to prepare its computer systems for the year
2000 and is addressing the year 2000 issues. The Company has implemented year
2000 compliant systems in a number of areas, including order entry systems. The
Company plans to have necessary modifications made to its other critical systems
and applications by the end of 1998 and to complete testing by 1999. The
Company, however, has little direct control over whether its suppliers will make
the appropriate modifications to their systems and applications on a timely
basis. The Company is implementing a vendor compliance program.
Operating expenses include costs incurred in preparing systems and applications
for the year 2000. The Company expects to incur internal staff costs as well as
outside services (including consultants) and other expenses related to the
conversion and testing of the systems and applications. These costs, which are
expensed as incurred, have been immaterial to date. Based on assessments
completed to date and compliance plans in process, the Company does not expect
that the year 2000 issues will have a material effect on its business operations
or results of operations. However, if appropriate modifications are not made by
the Company's suppliers on a timely basis, or if the Company's actual costs or
timing for the year 2000 conversion differ materially from its present
estimates, the Company's operations and financial results could be significantly
affected.
12
13
FORWARD-LOOKING INFORMATION
- ---------------------------
This Form 10-Q contains statements concerning certain trends and other
forward-looking information affecting or relating to the Company and its
industry that are intended to qualify for the protections afforded
"forward-looking statements" under the Private Securities Litigation Reform Act
of 1995. There are many important factors that could cause actual results to
differ materially from those in the forward-looking statements. Many of these
important factors are outside STERIS's control. Changes in market conditions,
including competitive factors and changes in government regulations, could cause
actual results to differ materially from the Company's expectations. No
assurance can be provided as to any future financial results. Other potentially
negative factors that could cause actual results to differ materially from those
in the forward-looking statements include (a) the possibility that the
continuing integration of acquired businesses will take longer than anticipated,
(b) the potential for increased pressure on pricing that leads to erosion in
profit margins, (c) the possibility that market demand will not develop for new
technologies, products, and applications, (d) the potential effects of
fluctuations in foreign currencies, (e) the potential that the impact of
weakened currencies in Southeast Asia could spread to countries where the
Company does a sizable amount of business, and (f) the possibility of reduced
demand, or reductions in the rate of growth in demand, for the Company's
products.
PART II OTHER INFORMATION
ITEM 1 LEGAL PROCEEDINGS
- ------ -----------------
Reference is made to Part I, Item 1., Note G of this Report on Form 10-Q, which
is incorporated herein by reference.
ITEM 6 EXHIBITS AND REPORTS ON FORM 8-K
- ------ --------------------------------
(a) EXHIBITS
EXHIBIT NUMBER EXHIBIT DESCRIPTION
-------------- -------------------
27.1 Financial Data Schedule
13
14
(b) REPORTS ON FORM 8-K
Item 5. Other Events. On August 24, 1998, STERIS Corporation effected a
two-for-one split of the Company's common shares through a 100% stock dividend
at the rate of one common share for each common share held by shareholders of
record on August 10, 1998.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. With
respect to the August 24, 1998 stock split, STERIS filed the press release
"STERIS Reports Record Fiscal First Quarter Results; Announces 2-for-1 Stock
Split" dated July 28, 1998.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
STERIS Corporation
(Registrant)
/s/ Michael A. Keresman, III
-----------------------------------
Michael A. Keresman, III
Chief Financial Officer and
Senior Vice President
(Principal Financial Officer)
November 13, 1998
14
5
6-MOS
MAR-31-1999
SEP-30-1998
25,077
0
196,599
0
110,619
372,950
322,394
(97,613)
825,032
176,233
0
0
0
233,616
161,592
825,032
364,900
364,900
194,082
194,082
0
0
4,719
54,287
21,171
33,116
0
0
0
33,116
0.49
0.47
